- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07259304
Social sundhed, aktivitetsadfærd og livskvalitet blandt unge voksne kræftoverlevere
Social sundhed, aktivitetsadfærd og livskvalitet blandt unge voksne kræftoverlevere: Et longitudinalt studie
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer patients aged 18-39 years. The study follows participants over four clinically significant timepoints in the first 12 months after diagnosis (baseline near diagnosis, mid treatment, near end of treatment, and 12 month follow up). At each timepoint, patients complete questionnaires and wear a wrist worn accelerometer for one week.
Studieoversigt
Status
Betingelser
- Ondartet fast neoplasma
- Hodgkin lymfom
- Anatomisk fase I brystkræft AJCC v8
- Anatomisk fase IA brystkræft AJCC v8
- Anatomisk fase IB brystkræft AJCC v8
- Anatomisk fase II brystkræft AJCC v8
- Anatomisk fase IIA brystkræft AJCC v8
- Anatomisk fase IIB brystkræft AJCC v8
- Anatomisk fase III brystkræft AJCC v8
- Anatomisk fase IIIA brystkræft AJCC v8
- Anatomisk fase IIIB brystkræft AJCC v8
- Anatomisk fase IIIC brystkræft AJCC v8
- Prognostisk fase I brystkræft AJCC v8
- Prognostisk stadium IA brystkræft AJCC v8
- Prognostisk stadium IB brystkræft AJCC v8
- Prognostisk fase II brystkræft AJCC v8
- Prognostisk fase IIA brystkræft AJCC v8
- Prognostisk fase IIB brystkræft AJCC v8
- Prognostisk fase III brystkræft AJCC v8
- Prognostisk fase IIIA brystkræft AJCC v8
- Prognostisk stadium IIIB brystkræft AJCC v8
- Prognostisk fase IIIC brystkræft AJCC v8
- Non-Hodgkin lymfom
- Stadie III livmoderlegemekræft AJCC v8
- Klinisk fase III kutan melanom AJCC v8
- Patologisk trin IIIB kutan melanom AJCC v8
- Patologisk fase IIIC kutan melanom AJCC v8
- Patologisk fase IIID kutan melanom AJCC v8
- Klinisk fase I kutan melanom AJCC v8
- Klinisk fase IA kutan melanom AJCC v8
- Klinisk fase IB kutan melanom AJCC v8
- Klinisk fase II kutan melanom AJCC v8
- Klinisk fase IIA kutan melanom AJCC v8
- Klinisk fase IIB kutan melanom AJCC v8
- Klinisk fase IIC kutan melanom AJCC v8
- Patologisk fase I kutan melanom AJCC v8
- Patologisk stadium IA kutan melanom AJCC v8
- Patologisk stadium IB kutan melanom AJCC v8
- Patologisk fase II kutan melanom AJCC v8
- Patologisk fase IIA kutan melanom AJCC v8
- Patologisk fase IIB kutan melanom AJCC v8
- Patologisk stadium IIC kutan melanom AJCC v8
- Patologisk trin III kutan melanom AJCC v8
- Patologisk trin IIIA kutan melanom AJCC v8
- Fase III kolorektal cancer AJCC v8
- Fase IIIA tyktarmskræft AJCC v8
- Fase IIIB tyktarmskræft AJCC v8
- Fase IIIC tyktarmskræft AJCC v8
- Fase I tyktarmskræft AJCC v8
- Fase II kolorektal cancer AJCC v8
- Fase IIA kolorektal cancer AJCC v8
- Fase IIB tyktarmskræft AJCC v8
- Fase IIC kolorektal cancer AJCC v8
- Fase I Livmoderhalskræft AJCC v8
- Fase IA Livmoderhalskræft AJCC v8
- Stadie IA1 Livmoderhalskræft AJCC v8
- Fase IA2 Livmoderhalskræft AJCC v8
- Stadie IB livmoderhalskræft AJCC v8
- Stadie IB1 Livmoderhalskræft AJCC v8
- Stadie IB2 Livmoderhalskræft AJCC v8
- Fase II livmoderhalskræft AJCC v8
- Stadie IIA Livmoderhalskræft AJCC v8
- Fase IIA1 Livmoderhalskræft AJCC v8
- Fase IIA2 Livmoderhalskræft AJCC v8
- Stadie IIB Livmoderhalskræft AJCC v8
- Stadie III livmoderhalskræft AJCC v8
- Stadie IIIA Livmoderhalskræft AJCC v8
- Stadie IIIB Livmoderhalskræft AJCC v8
- Stadie IIIA Livmoderlegemekræft AJCC v8
- Stadie IIIB Livmoderhalskræft AJCC v8
- Stadie IIIC livmoderlegemekræft AJCC v8
- Stadie IIIC1 Livmoderlegemekræft AJCC v8
- Stadie IIIC2 Livmoderlegemekræft AJCC v8
- Ondartet hjerneneoplasma
- Fase III Kræft i æggestokkene AJCC v8
- Fase IIIA Ovariekræft AJCC v8
- Fase IIIA1 Kræft i æggestokkene AJCC v8
- Fase IIIA2 Kræft i æggestokkene AJCC v8
- Fase IIIB Ovariekræft AJCC v8
- Stadie IIIC Ovariekræft AJCC v8
- Neoplasma i centralnervesystemet
- Stage III differentieret skjoldbruskkirtelcarcinom AJCC v8
- Stadie III Skjoldbruskkirtel Medullært karcinom AJCC v8
- Stadie I Uterin Corpus Cancer AJCC v8
- Stadie IA Livmoderkroppskræft AJCC v8
- Stadie IB livmoderlegemekræft AJCC v8
- Stadie II livmoderlegemekræft AJCC v8
- Ondartet testikel-neoplasma
- Fase II Kræft i æggestokkene AJCC v8
- Fase IIA Kræft i æggestokkene AJCC v8
- Fase IIB Ovariekræft AJCC v8
- Fase I Ovariekræft AJCC v8
- Fase IA Kræft i æggestokkene AJCC v8
- Stadie IB Kræft i æggestokkene AJCC v8
- Stadie IC Ovariekræft AJCC v8
- Ondartet knogleneoplasma
- Stage I Differentieret Skjoldbruskkirtelcancer AJCC v8
- Stadium I medullært skjoldbruskkirtelcarcinom AJCC v8
- Stadium II Differentieret Skjoldbruskkirtelcarcinom AJCC v8
- Stadium II medullært skjoldbruskkirtelcarcinom AJCC v8
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. Characterize trajectories of social health over the course of cancer treatment and into early survivorship; II. Investigate longitudinal and potentially reciprocal associations between social health and activity behaviors (physical activity and sedentary time) and their relationship to quality of life; III. Examine whether gender, race/ethnicity, socioeconomic status, and symptom burden moderate these associations.
OUTLINE:
Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forenede Stater, 90033
- Los Angeles General Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- MD Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.
Beskrivelse
Inclusion Criteria:
- Age 18-39 years at cancer diagnosis.
- Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer.
- Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging).
- Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center.
- Clinician assessed expected survival greater than 12 months at time of diagnosis.
- Able to complete questionnaires and wear a wrist worn accelerometer.
- English or Spanish speaking.
Exclusion Criteria:
- Leukemia (excluded due to longer treatment duration and different care trajectory).
- Primary language other than English or Spanish.
- Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Observational (actigraph, surveys)
Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months. |
Wear an actigraph GT3X-BT accelerometer Complete survey
Andre navne:
Complete survey |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in social role functioning
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation). |
Baseline up to 1 year
|
|
Change in perceived emotional support
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support). |
Baseline up to 1 year
|
|
Change in perceived informational support
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support). |
Baseline up to 1 year
|
|
Change in perceived instrumental support
Tidsramme: Baseline up to 1 year
|
Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support). |
Baseline up to 1 year
|
|
Change in loneliness score
Tidsramme: Baseline up to 1 year
|
Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness). |
Baseline up to 1 year
|
|
Change in social anxiety symptoms
Tidsramme: Baseline up to 1 year
|
Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety). |
Baseline up to 1 year
|
|
Change in social network density
Tidsramme: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network). |
Baseline up to 1 year
|
|
Change in proportion of supportive social ties
Tidsramme: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network). |
Baseline up to 1 year
|
|
Change in frequency of social contact
Tidsramme: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact). |
Baseline up to 1 year
|
|
Change in total daily physical activity
Tidsramme: Baseline up to 1 year
|
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity). |
Baseline up to 1 year
|
|
Change in total daily sedentary time
Tidsramme: Baseline up to 1 year
|
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time). |
Baseline up to 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Quality of Life
Tidsramme: Baseline up to 1 year
|
Patient reported quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10, assessed at baseline and 12 month follow up. This is a 10-item patient-reported questionnaire measuring general physical, mental, and social health. Most questions use a 1-to-5 point scale. Higher numerical values consistently represent better health or lower symptoms. The survey produces two separate scores: Global Physical Health (GPH) and Global Mental Health (GMH). Raw response values are summed and converted into standardized T-scores where a score of 50 represents the U.S. general population average (standard deviation of 10). |
Baseline up to 1 year
|
|
Symptom Burden
Tidsramme: Baseline up to 1 year
|
Symptom burden assessed using the MD Anderson Symptom Inventory (MDASI) at all four timepoints. This survey is a multi-symptom patient-reported outcome (PRO) measure used to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. |
Baseline up to 1 year
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Kimberly Miller, PhD, University of Southern California
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Knoglesygdomme
- Muskuloskeletale sygdomme
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Mandlige urogenitale sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Neoplasmer i endokrine kirtler
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Tyktarmssygdomme
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Karcinom
- Livmoderhalssygdomme
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Lymfom
- Neoplasmer i nervesystemet
- Uterine neoplasmer
- Neuroendokrine tumorer
- Neoplasmer, duktale, lobulære og medullære
- Karcinom, neuroendokrin
- Testikelsygdomme
- Hemiske og lymfatiske sygdomme
- Kolorektale neoplasmer
- Ovariale neoplasmer
- Uterine cervikale neoplasmer
- Lymfom, Non-Hodgkin
- Hodgkins sygdom
- Neoplasmer i hjernen
- Neoplasmer i centralnervesystemet
- Karcinom, medullær
- Testikulære neoplasmer
- Knogleneoplasmer
Andre undersøgelses-id-numre
- 0S-20-10
- P30CA014089 (U.S. NIH-bevilling/kontrakt)
- 0S-20-10 (Anden identifikator: USC / Norris Comprehensive Cancer Center)
- NCI-2021-05723 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R37CA256867 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .